Broad Pharma's first case of yttrium [90Y] resin microglobulular liver cancer has a remarkable therapeutic effect

Shanghai Securities News China Securities Network News (reporter Zhang Xue) Recently, Yuanda Pharmaceutical's global innovative product SIR-Spheres yttrium [90Y] resin microspheres in China's first case of licensed access to clinical treatment of liver cancer patients the latest situation. On December 24, a team of experts led by Dong Jiahong, academician of the Chinese Academy of Engineering and president of Beijing Tsinghua Changgeng Hospital, announced the results. Through the clinical treatment of yttrium [90Y] resin microspheres, patients with primary liver cancer (CNLC STAGE IIIa) have been given the possibility of further surgery and complete cure, which also marks that the field of liver malignancy treatment in China has ushered in an international innovative and precise interventional radiation therapy program, which is of landmark significance.

According to the clinical effect, within 3 months after surgery, the patient's liver tumor was reduced from the preoperative unresectable state to one-tenth of the original tumor volume, and the alpha-fetoprotein (AFP), which is a specific marker of primary liver cancer, has also dropped from 180446ng/ml before surgery by nearly 120 times to the current 1469ng/ml. It is reported that the patient was diagnosed with primary liver cancer (CNLC STAGE IIIa) in June, which has exceeded the standards of various liver transplants at home and abroad, and because the reserved liver volume is less than 40%, it cannot be routinely removed surgically.

Yttrium [90Y] resin microspheres are one of the blockbuster products of Yuanda Pharmaceutical, and it is also the first radioactive microsphere for liver malignancy officially approved by the US FDA, which has been treated more than 120,000 times in more than 50 countries and regions around the world, without obvious adverse reactions, and its safety and efficacy have been fully verified, and recommended by mainstream diagnosis and treatment guidelines in China, the United States and Europe. In November 2020, Yuanda Pharmaceutical submitted an application for the listing of yttrium [90Y] resin microspheres to the State Food and Drug Administration and was accepted by the State Food and Drug Administration, and the company said that the product is expected to be approved for listing in China at the end of this year or early next year.

According to reports, in addition to salvage treatment and first-line treatment of various malignant tumors for patients with surgical contraindications, yttrium [90Y] resin microsphere precision internal radiation therapy or other treatments can also reduce the staging of patients with hepatocellular carcinoma, bowel cancer liver metastasis and bile duct cancer, making it more suitable for surgical resection, and can also reduce tumor load, slow down the disease process and provide a bridge for liver transplantation.